Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 18, 2009

View Archived Issues

Apoptosis inducers in early development at Chinese Academy of Medical Science

AstraZeneca reports second quarter 2009 results

VAK-694 safety and tolerability to be assessed by Novartis in allergic rhinitis phase II trial

Gilead presents studies of its pharmaco-enhancer GS-9350 in the treatment of HIV

Xinchang Pharmaceutical Factory claims novel anticancer compounds

Merz discloses mGluR5 modulators for the treatment of pain

Sativex is well tolerated and improves spasticity due to multiple sclerosis in clinical trial

ACE-011 active against bone loss in postmenopausal women

TBR-652 in vitro activity in combination with antiretrovirals and human pharmacokinetics reported

Botulinum toxin type A improves various Parkinson's disease symptoms

ONO-5334 shows potential for osteoporosis therapy in ovariectomized monkeys

Cell Therapeutics reports 18-month follow-up data from phase III pixantrone study

Biovex and FDA agree on design for pivotal phase III OncoVEX(GM-CSF) study

Cytavis initiates phase II aviscumine trial in metastatic colorectal carcinoma

DNage initiates observational study in children with Cockayne syndrome

EMEA recommends orphan drug designation of intravenous CP-4126 for pancreatic cancer

European Commission approves expanded use for raltegravir in adults with HIV

FDA clears D3 FastPoint L-DFATM respiratory virus identification kit

Hyperion Therapeutics enrolls first patient in HPN-100 trial in children with urea cycle disorders

Lexicon initiates phase II trial of LX-4211 in type 2 diabetes

Poniard presents update on pivotal phase III picoplatin trial in lung cancer

FDA grants orphan drug designation to Restanza for plague and tularemia

RX-100 shows potential in protecting against lethal whole-body radiation

ZaBeCor begins phase II Excellair trial in asthma patients

Seaside Therapeutics secures funding to support studies in autism and fragile X syndrome

FDA approves Valturna, a single-pill combination of aliskiren and valsartan

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...